Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

Doom_Gloom_AR Feb. 6 at 12:11 AM

$CRVO this would be up today 😂😆😂

0 · Reply

LowCountryHooker Feb. 5 at 3:43 PM

$CRVO this might be a first for my ticker list.

3 · Reply

Messerschmittbf109 Feb. 4 at 10:41 PM

$CRVO 🦠 worst of a virus

0 · Reply

BPler Feb. 4 at 7:56 PM

$CRVO The bleeding down and low volume of a nano cap while number of watchers is over 22k. Nothing makes sense with this one regarding price action.

1 · Reply

Messerschmittbf109 Feb. 4 at 5:47 PM

$CRDF $BBNX $CRVO Weeks of down . And today is capitulation 💩

2 · Reply

CWL123 Feb. 4 at 5:36 PM

$CRVO complete effing garbage

0 · Reply

Messerschmittbf109 Feb. 4 at 8:38 AM

$NVO $CRVO $CRDF $LLY If it had been a Japanese company, Novo …..the entire board would have gotten out of the way and apologized. But between the United States and Europe, they are getting closer to the Chinese, they are wrong and the only ones who lose out are the shareholders.

1 · Reply

Scorpole Feb. 3 at 5:05 PM

$CRVO Offering and 20 mill new shares and result of that - R/S in 2027

1 · Reply

Messerschmittbf109 Feb. 3 at 4:38 PM

$CRVO not. A serious stock I believed… I made a big wrong

0 · Reply

Doom_Gloom_AR Feb. 3 at 3:34 PM

$CRVO let her sink a little more, keep your heads down, crawl on bellies, wait till you see the white of their eyes.

1 · Reply

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 2 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 2 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 3 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 4 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 5 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 6 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 6 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 9 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 11 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 11 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 11 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 11 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 2 years ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Doom_Gloom_AR Feb. 6 at 12:11 AM

$CRVO this would be up today 😂😆😂

0 · Reply

LowCountryHooker Feb. 5 at 3:43 PM

$CRVO this might be a first for my ticker list.

3 · Reply

Messerschmittbf109 Feb. 4 at 10:41 PM

$CRVO 🦠 worst of a virus

0 · Reply

BPler Feb. 4 at 7:56 PM

$CRVO The bleeding down and low volume of a nano cap while number of watchers is over 22k. Nothing makes sense with this one regarding price action.

1 · Reply

Messerschmittbf109 Feb. 4 at 5:47 PM

$CRDF $BBNX $CRVO Weeks of down . And today is capitulation 💩

2 · Reply

CWL123 Feb. 4 at 5:36 PM

$CRVO complete effing garbage

0 · Reply

Messerschmittbf109 Feb. 4 at 8:38 AM

1 · Reply

Scorpole Feb. 3 at 5:05 PM

$CRVO Offering and 20 mill new shares and result of that - R/S in 2027

1 · Reply

Messerschmittbf109 Feb. 3 at 4:38 PM

$CRVO not. A serious stock I believed… I made a big wrong

0 · Reply

Doom_Gloom_AR Feb. 3 at 3:34 PM

$CRVO let her sink a little more, keep your heads down, crawl on bellies, wait till you see the white of their eyes.

1 · Reply

Messerschmittbf109 Feb. 3 at 2:46 PM

$CRVO bandits … we need a sheriff to kick ass these bandits

0 · Reply

Pharoh42 Feb. 2 at 9:32 PM

$CRVO What a pathetic pos A whole fukn company with approved fkn drug , board and managers raking millions of compensation every year and this stupid shit is bleeding everyday , about to go to zero Not a fucken move

1 · Reply

Messerschmittbf109 Feb. 2 at 9:18 PM

$CRVO these are professional scoun drels They can change the name but always thi e v€s are Merdomed to the hell…

1 · Reply

Nochtar Feb. 2 at 8:08 PM

$CRVO after 6y. . they changed the name, but the shit stays the same

1 · Reply

Messerschmittbf109 Feb. 2 at 7:48 PM

$CRVO $CRDF Sec must Close these coffee shops sooon ! We don’t need others smoke stocks $ELPW $PHOE shame Thanks

0 · Reply

Stu_padasso Feb. 2 at 7:19 PM

$CRVO looks like under 2 would be a good loading zone

1 · Reply

Ghostofgreg1 Jan. 30 at 3:31 PM

$CRVO Cant believe it They got away with it again Pump Dump rinse repeat 4’s…….3’s……2’s……reverse split All over again and again Damn these crooks

1 · Reply

Messerschmittbf109 Jan. 30 at 3:18 PM

$CRVO oooo and so under 5 Thie V€s ! nice eeek end

0 · Reply

BPler Jan. 30 at 2:27 PM

$CRVO DD on reddit, but it looks like the market is sliding today again down. Maybe the bleeding down is attractive for new buyers, quite painful overall market these days tbh. https://www.reddit.com/r/pennystocks/comments/1qq3xv9/dd_crvo_cervomed_inc/

2 · Reply

BPler Jan. 30 at 2:17 PM

$CRVO Vanguard Group reported in F13 SEC yesterday that they didn't sell their shares, they even increased by 3% owning now over 350k shares. $VTI

1 · Reply

BillionerOfKing Jan. 29 at 10:19 PM

$CRVO Current Stock Price: $5.12

0 · Reply

Messerschmittbf109 Jan. 29 at 10:11 PM

$CRVO but they are finest specialists 🙅🏻 Vacuum of words Nobel

0 · Reply

Market Cap	43.21M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	83,400
Avg Vol	68,412
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	5%
Beta	-0.82
Analysts	Strong Sell
Price Target	$22.83